Transaminase mutant and application thereof in preparation of sitagliptin intermediates

Patent metadata

Field	Value
Publication number	US-12378588-B2
Application number	US-202117778627-A
Country	US
Kind code	B2
Filing date	Jan 21, 2021
Priority date	Oct 26, 2020
Publication date	Aug 5, 2025
Grant date	Aug 5, 2025

Abstract

The present invention discloses a transaminase mutant and application thereof in preparation of sitagliptin intermediates, the transaminase mutant is obtained by substitution of tyrosine with proline at position 74, substitution of glutamic acid with aspartic acid at position 228, substitution of leucine with alanine at position 254 and substitution of methionine with threonine at position 290 of the amino acid sequence shown in SEQ ID NO: 2. The present invention uses wet cells or a purified transaminase as a biocatalyst and a sitagliptin precursor ketone or a prochiral carbonyl compound as a substrate to prepare a sitagliptin intermediate or a sitagliptin ester intermediate; the total yield of the method reaches about 82%, and e.e. value of the product reaches 99%.

First claim

The invention claimed is:

1. A transaminase mutant, wherein the transaminase mutant is obtained by substitution of tyrosine with proline at position 74, substitution of glutamic acid with aspartic acid at position 228, substitution of leucine with alanine at position 254 and substitution of methionine with threonine at position 290 of the amino acid sequence shown in SEQ ID NO: 2.

2. An encoding gene of the transaminase mutant as claimed in claim 1 , wherein the nucleotide sequence of the encoding gene is shown in SEQ ID NO: 3.

3. A recombinant genetically engineered strain transformed by the encoding gene of the transaminase mutant as claimed in claim 2 .

4. A method for biocatalytic synthesis of a sitagliptin intermediate from a sitagliptin precursor ketone using the transaminase mutant as claimed in claim 1 in the presence of the transaminase mutant of claim 1 , wherein the method comprises:
constructing a reaction system comprising wet cells or a purified transaminase as a biocatalyst, [1-piperidinyl]-4-[2,4,5-trifluorophenyl]-1,3-butanedione as a substrate, dimethyl sulfoxide as a cosolvent, pyridoxal phosphate as a coenzyme, isopropyl amine as a cosubstrate, and a pH 8-9 triethanolamine buffer as a reaction medium; and
carrying out a biocatalytic reaction is carried out at 30-45° C. and 100-250 r/min, after the reaction is completed, subjecting the reaction solution to separation and purification to obtain (R)-3-amino-I-(I-piperidinyl)-4-(2,4,5-trifluorophenyl)-I-butanone,
wherein the wet cells are obtained by fermentation culture of a recombinant genetically engineered bacterium bacteria containing an encoding gene encoding the of a transaminase mutant and the purified transaminase is obtained by subjecting the wet cells to ultrasonication and then extraction.

5. The method as claimed in claim 4 , wherein in the reaction system, an amount of the wet cells is 10-100 g/L, an amount of the purified transaminase is 0.01-1.0 g/L, a final concentration of the substrate is 2-50 g/L, a final concentration of dimethyl sulfoxide is 10-40% (v/v), a final concentration of pyridoxal phosphate is 0.5 g/L, and a final concentration of isopropyl amine is 10 g/L.

6. A method for biocatalytic synthesis of a sitagliptin ester intermediate from a prochiral carbonyl compound in the presence of the transaminase mutant as claimed in claim 1 , the method comprising reacting the prochiral compound in the presence of the transaminase and an amino donor to produce the sitagliptin ester intermediate, wherein the prochiral carbonyl compound is one selected from the group consisting of the following compounds: 3-carbonyl-4-(2,4,5-trifluorophenyl)-butyric acid methyl ester, 3-carbonyl-4-(2,4,5-Trifluorophenyl)-butyric acid propyl ester, 3-carbonyl-4-(2,4,5-trifluorophenyl)-butyric acid isopropyl ester, 3-carbonyl-4-(2,4,5-trifluorophenyl)-butyric acid ethyl ester, 3-carbonyl-4-(2,4,5-trifluorophenyl)-butyric acid isobutyl ester and 3-carbonyl-4 (2,4,5-trifluorophenyl) butyric acid benzyl ester.

7. The method as claimed in claim 6 , wherein the method comprises:
constructing a reaction solution system comprising wet cells as a biocatalyst, the prochiral carbonyl compound as a substrate, dimethyl sulfoxide as a cosolvent, pyridoxal phosphate as a coenzyme, isopropyl amine as a cosubstrate, and a pH 8-9 triethanolamine buffer as a reaction medium; and
carrying out a biocatalytic reaction at 25-35° C. and 100-250 r/min, after the reaction is completed, subjecting the reaction solution to separation and purification to obtain the sitagliptin ester intermediate; in which, the wet cells are obtained by a fermentation culture of a recombinant genetically engineered bacterium bacteria containing an encoding gene encoding the transaminase mutant.

8. The method as claimed in claim 7 , wherein in the reaction system, an amount of the wet cells is 10-100 g/L, a final concentration of the substrate is 2-60 g/L, a final concentration of dimethyl sulfoxide is 10-40% (v/v), a final concentration of pyridoxal phosphate is 0.5 g/L, and a final concentration of isopropyl amine is 10 g/L.

9. The method as claimed in claim 4 , wherein the wet cells are prepared as follows: the recombinant Escherichia coli genetically engineered bacterium strain containing the encoding gene of the transaminase mutant is inoculated into LB liquid medium containing 50 μg/ml kanamycin, cultured at 37° C. and 200 rpm for 12 hours to produce an inoculum, the resulting inoculum is inoculated at a 1% volume into fresh LB liquid medium containing 50 μg/ml kanamycin with 1% incubating volume and cultured at 37° C. and 150 rpm to produce a culture; when OD600 of the culture reaches 0.6-0.8, IPTG is added with a final concentration of 0.1 mM, and the culture bacteria solution is subjected to induction culture at 28° C. for 12 hours to produce a resulting solution; the resulting solution is subjected to centrifugation at 4° C. and 5000 rpm for 20 min to produce a supernatant and sediment, the resulting supernatant is discarded and the sediment is collected, thereby obtaining the wet cells.

Assignees

• Zhejiang Yongtai Technology Co Ltd
• Univ Zhejiang Technology
• Zhejiang yongtai pharmaceutical co ltd

Inventors

• Liu Zhiqiang
• Cheng Feng
• Zhang Xiaojian
• Jia Dongxu
• Zheng Yuguo
• He Renbao
• Jin Yizhong
• Shao Hongming
• Lin Jiaohua
• Zhang Feng

Classifications

• C12Y206/01018

  Beta-alanine-pyruvate transaminase (2.6.1.18) · CPC title

• C12N2800/101

  for bacteria · CPC title

• C12N15/70

  Vectors or expression systems specially adapted for E. coli · CPC title

• C12N9/1096 Primary

  transferring nitrogenous groups (2.6) · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title